Article

ER degradation for ER+/HER2‒ advanced or metastatic breast cancer: a phase 1 trial

2025-09-11

Abstract excerpt

<title>Abstract</title> <p>AC699, an oral, novel chimeric estrogen receptor-α (ERα) binds, ubiquitinates, and degrades ERα by engaging cereblon E3 ligase. We report AC699 (100‒600 mg daily), safety/tolerability, and preliminary antitumor efficacy from a first-in-human, phase 1, dose-escalation study in 37 patients with heavily-pretreated, locally-advanced/metastatic ER+/HER2- breast cancer. 78% of patients had tr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: af641136-338d-545a-9a23-2adb929354e1
DOI: 10.21203/rs.3.rs-5397125/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

ER degradation for ER+/HER2‒ advanced or metastatic breast cancer: a phase 1 trialDOI 10.21203/rs.3.rs-5397125/v1Read

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.Semantic proximity Read

Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer In Vitro and In VivoSemantic proximity Read

Real-world data of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer centerSemantic proximity Read

SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD) effectively shrinks tumors both in intracranial and subcutaneous ER+ breast cancer modelsSemantic proximity Read

Targeted therapies for ER+/HER2- metastatic breast cancerSemantic proximity Read

Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast CancerSemantic proximity Read

Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies.Semantic proximity Read

A Novel Oral Selective Estrogen Receptor Degrader TFX06 Suppresses In Vivo Growth of ESR1 Wild-Type and Mutant TumorsSemantic proximity Read

Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.Semantic proximity Read

ERO1α as a potential drug target for breast cancer: a systematic review of current evidenceSemantic proximity Read

Elacestrant in metastatic breast cancer: current advancements and future perspectives.Semantic proximity Read

Endocrine resistance in breast cancer--An overview and update.Semantic proximity Read